Cost-effectiveness of ximelagatran for stroke prevention.
Perret-Guillaume
Christine
C
Wahl
Denis
D
D000925:Anticoagulants / Q000191:economics* / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy* / Q000191:economics; D001384:Azetidines / Q000191:economics* / Q000627:therapeutic use; D001596:Benzylamines; D003362:Cost-Benefit Analysis; D006801:Humans; D011355:Prodrugs / Q000191:economics* / Q000627:therapeutic use; D019057:Quality-Adjusted Life Years; D020521:Stroke / Q000191:economics / Q000209:etiology / Q000517:prevention & control*; D014859:Warfarin / Q000191:economics* / Q000627:therapeutic use
D000925:Anticoagulants; D001384:Azetidines; D001596:Benzylamines; D011355:Prodrugs; C426686:ximelagatran; D014859:Warfarin